A medically supervised program for adults with obesity or weight-related metabolic conditions, built on your labs and monitored by a licensed provider.
Your baseline panel tells your provider where your metabolism actually stands. From there, medication is one option among several, prescribed only where it is clinically appropriate.
Metabolic panel, A1c, insulin and lipids establish where your metabolism actually stands.
A licensed provider determines whether GLP-1 therapy is appropriate for you.
Compounded or branded GLP-1 medications shipped to your door from certified pharmacy partners.
Nutrition guidance and body-composition tracking to hold a healthy metabolic set point.
GLP-1 therapies are prescribed only where clinically appropriate, following evaluation by a licensed provider. Compounded medications are not FDA-approved finished drug products. Individual results vary.
Start with your baseline and find out whether a GLP-1 protocol is right for you.
Zepbound targets two hunger hormones, GIP and GLP-1. In clinical trials of Zepbound® (tirzepatide), adults lost an average of up to 21% of body weight over 72 weeks alongside diet and exercise.
FDA Approved for Weight Loss
Mounjaro (tirzepatide) is FDA-approved for the treatment of type 2 diabetes. It is not approved for weight management.
FDA Approved for Type 2 Diabetes
Ozempic (semaglutide) is FDA-approved for the treatment of type 2 diabetes. It is not approved for weight management. If a licensed provider determines that a GLP-1 therapy is appropriate for weight management, they will discuss the medications approved for that use.
FDA Approved for Type 2 Diabetes
Wegovy, designed specifically for weight management, comes as a once-weekly injection with a higher dosage than Ozempic, resulting in more substantial weight loss. In clinical trials, individuals using Wegovy for weight loss experienced an average weight loss of 15%.
FDA Approved for Weight Loss
Oral semaglutide — the Wegovy pill, with no injections. In a 64-week clinical study of 307 adults, those taking Wegovy pills lost an average of 33 lbs, or 14% of their body weight, against 6 lbs on placebo. 8 in 10 lost at least 5% of their weight and 1 in 4 lost 20% or more. Shipped to your door through the Wegovy Direct program.
FDA Approved for Weight Loss
Foundayo (orforglipron) is Eli Lilly’s once-daily GLP-1 weight loss pill — the first oral GLP-1 you can take any time of day, with no food or water restrictions. In the Phase 3 ATTAIN program of more than 4,500 adults, participants on the highest dose lost about 12.4% of body weight (~27 lbs) against 0.9% on placebo.
FDA Approved for Weight Loss
Rybelsus is the brand name for oral semaglutide, a pioneering medication designed for the management of type 2 diabetes. It is the first GLP-1 receptor agonist available in a tablet form, eliminating the need for injections. Rybelsus works by enhancing insulin secretion and suppressing appetite. Rybelsus is not FDA approved for weight loss.
Not FDA approved for weight loss
Liraglutide is a GLP-1 receptor agonist that helps regulate blood sugar and reduce appetite. FDA-approved brand-name versions include Victoza (for type 2 diabetes) and Saxenda (for weight management). Compounded liraglutide is prepared by state-licensed compounding pharmacies. It is not an FDA-approved finished drug product. Your provider will discuss which option, if any, is appropriate for you.
Brand and compounded options
Metformin (metformin hydrochloride) is FDA-approved for the treatment of type 2 diabetes. It is not approved for weight management. It improves insulin sensitivity and helps control blood sugar. Research into metformin and healthy ageing is ongoing and outcomes vary between individuals. If a licensed provider determines it is clinically appropriate for you, they will discuss whether it fits your plan.
FDA Approved for Type 2 DiabetesResults vary. Clinical trial results apply only to the FDA-approved branded medication specifically identified and do not apply to compounded medications. All medications must be prescribed by a licensed provider based on medical necessity. Zepbound® and Mounjaro® are registered trademarks of Eli Lilly and Company. Wegovy®, Ozempic®, Rybelsus®, Saxenda® and Victoza® are registered trademarks of Novo Nordisk A/S. Foundayo® (orforglipron) is a registered trademark of Eli Lilly and Company. AgeDefy is not affiliated with, endorsed by, or sponsored by these manufacturers. All prescriptions require a medical evaluation by a licensed provider. Compounded medications are not FDA-approved finished drug products. Individual results vary.
If you have tried dieting, calorie counting, or other programs without lasting results, you are not alone and you are not failing. Medical weight loss with FDA-approved GLP-1 medications works differently because it addresses the hormonal drivers of appetite, not just willpower.
See if you qualifyMost adults who qualify meet one or more of the following:
This is general information, not medical advice. A licensed provider determines eligibility after reviewing your history and labs.
Enter your weight and height to see your BMI.
BMI is a screening tool, not a diagnosis. It does not distinguish muscle from fat. Your provider will interpret it alongside your labs and history.
See if you qualifyA continuous glucose monitor tracks your blood sugar around the clock, so you and your provider can see how your body responds to food, sleep and activity — not just what the scale says. Prescribed where clinically appropriate and reviewed alongside your labs.
Continuous glucose monitors are prescription devices. A licensed provider determines whether monitoring is appropriate for you. Not a diagnostic service and not a substitute for medical advice.
